ABC Arbitrage SA Acquires New Shares in Evotec AG (NASDAQ:EVO)

Key Points

• ABC Arbitrage SA acquired 77,919 shares of Evotec AG, valued at around $260,000, according to their recent Form 13F filing with the SEC.
• Institutional investors have shown significant interest in Evotec, with DCF Advisers LLC increasing its stake by 227% and Bank of America boosting its stake by 262.5% in recent quarters.
• Evotec's stock has seen price fluctuations, with a 1-year low of $2.84 and a high of $5.64, while several analysts have upgraded their ratings on the company recently.

ABC Arbitrage SA bought a new position in shares of Evotec AG (NASDAQ:EVO - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 77,919 shares of the company's stock, valued at approximately $260,000.

Several other institutional investors and hedge funds have also bought and sold shares of EVO. BNP Paribas Financial Markets bought a new stake in Evotec in the fourth quarter valued at approximately $27,000. CSS LLC IL bought a new stake in Evotec in the 4th quarter valued at $50,000. Bank of America Corp DE lifted its holdings in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Lighthouse Investment Partners LLC bought a new stake in shares of Evotec during the 4th quarter worth about $166,000. Finally, DCF Advisers LLC grew its position in shares of Evotec by 227.0% in the first quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock valued at $2,510,000 after purchasing an additional 521,708 shares during the last quarter. Institutional investors own 5.81% of the company's stock.

Evotec Stock Performance

EVO stock traded up $0.07 during mid-day trading on Friday, hitting $3.93. The stock had a trading volume of 57,832 shares, compared to its average volume of 76,105. The firm has a fifty day simple moving average of $4.08 and a 200 day simple moving average of $3.99. Evotec AG has a 52 week low of $2.84 and a 52 week high of $5.64. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.03 and a quick ratio of 1.93.

Analyst Ratings Changes

EVO has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th.

Evotec Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.